Content Spotlight
Podcast: Sustainability equals efficiency, says eXmoor
eXmoor Pharma discusses the steps taken to build a more sustainable facility, the importance of its design, and calls for industry to share advice and initiatives.
Latest News
thumbnail
Facilities & CapacityLilly announces $3bn expansion to injectable drug manufacturing facility
Lilly announces $3bn expansion to injectable drug manufacturing facility
The pharma giant is expanding its site in Pleasant Prairie, Wisconsin after acquiring the facility from Nexus in April.
Deal-Making
Novo expands EU footprint with $200m Novavax plantNovo expands EU footprint with $200m Novavax plant
Danish pharma giant Novo Nordisk will acquire Novavax’s manufacturing facility in the Czech Republic.
Deal-Making
ATI and KBI team up to manufacture antagonistic antibody candidateATI and KBI team up to manufacture antagonistic antibody candidate
KBI will use its monoclonal antibody (mAb) platform to produce ATI’s lead candidate for clinical testing.
Facilities & Capacity
WuXi Apptec and WuXi Biologics shares surge as BIOSECURE stumblesWuXi Apptec and WuXi Biologics shares surge as BIOSECURE stumbles
The five Chinese companies targeted by the US government’s BIOSECURE Act receive a proverbial stay of execution.
Facilities & Capacity
Q&A: Robust supply chains and global networks are among key considerations when choosing an mRNA CDMOQ&A: Robust supply chains and global networks are among key considerations when choosing an mRNA CDMO
“The field continues to evolve, and the clinical potential of mRNA extends far beyond vaccines for infectious diseases,” says Lonza mRNA business unit head.
Global Markets
WuXi Apptec and WuXi Biologics shares surge as BIOSECURE stumblesWuXi Apptec and WuXi Biologics shares surge as BIOSECURE stumbles
The five Chinese companies targeted by the US government’s BIOSECURE Act receive a proverbial stay of execution.
Therapeutic Class
India’s pharma future relies on regulatory strengthIndia’s pharma future relies on regulatory strength
Fostering a culture of compliance and quality alignment with Western regulators is vital for India's biomanufacturing growth: “If you are open for business every day, you have to be ready for inspection every day.”
Regulations
Vaccine makers sanguine amid threat from US health nominees RFK Jr. and Dr. OzVaccine makers sanguine amid threat from RFK Jr. and Dr. Oz
Pfizer, Merck & Co., and Moderna remain upbeat over future dealings with the US government despite President-elect Trump telling vaccine-sceptic and alternative-medicine proponents to “go wild on health.”
Facilities & Capacity
IRA matches BIOSECURE in driving CDMO sector in IndiaIRA matches BIOSECURE in driving CDMO sector in India
While much talk at CPHI Milan centered on the potential impact of BIOSECURE, other US policies – particularly the Inflation Reduction Act (IRA) – are proving a boon for Indian CDMOs.
Therapeutic Class
.jpg?width=700&auto=webp&quality=80&disable=upscale)
Q&A: Robust supply chains and global networks are among key considerations when choosing an mRNA CDMOQ&A: Robust supply chains and global networks are among key considerations when choosing an mRNA CDMO
“The field continues to evolve, and the clinical potential of mRNA extends far beyond vaccines for infectious diseases,” says Lonza mRNA business unit head.
Therapeutic Class
Is India reliable? Addressing challenges in the pharma industryIs India reliable? Addressing challenges in the pharma industry
To reach its full potential, India must drop its ‘colonial mindset,’ says Biocon COO.
Upstream & Downstream Processing
Q&A: Robust supply chains and global networks are among key considerations when choosing an mRNA CDMOQ&A: Robust supply chains and global networks are among key considerations when choosing an mRNA CDMO
“The field continues to evolve, and the clinical potential of mRNA extends far beyond vaccines for infectious diseases,” says Lonza mRNA business unit head.
Upstream & Downstream Processing
Elections, GLPs, and a post-pandemic world: Thermo on the future of biotech investmentElections, GLPs, and a post-pandemic world: Thermo on the future of biotech investment
“Biotech funding is improving. It's not robust, but it's improving,” says Thermo Fisher’s CEO amid numerous reasons to be cheerful in an ever-changing world.